A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer
about
The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer.Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives.Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment.
P2860
A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A plasma cytokine and angiogen ...... h metastatic colorectal cancer
@ast
A plasma cytokine and angiogen ...... h metastatic colorectal cancer
@en
type
label
A plasma cytokine and angiogen ...... h metastatic colorectal cancer
@ast
A plasma cytokine and angiogen ...... h metastatic colorectal cancer
@en
prefLabel
A plasma cytokine and angiogen ...... h metastatic colorectal cancer
@ast
A plasma cytokine and angiogen ...... h metastatic colorectal cancer
@en
P2093
P2860
P356
P1433
P1476
A plasma cytokine and angiogen ...... h metastatic colorectal cancer
@en
P2093
De-Shen Wang
Dong-Liang Chen
Dong-Sheng Zhang
Feng-Hua Wang
Hui-Yan Luo
Miao-Zhen Qiu
P2860
P2888
P356
10.1038/SREP17717
P407
P50
P577
2015-12-01T00:00:00Z